Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6158162 | 0.83 | ALDH1A1 (0.61) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| SCHEMBL16544616 | 0.82 | HSD17B10 (0.65) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| SCHEMBL15739698 | 0.79 | ALDH1A1 (0.68) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| SCHEMBL660424 | 0.79 | ALDH1A1 (0.68) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| Hydrochloric Acid SCHEMBL28488097 | 0.78 | ALDH1A1 (0.66) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| SCHEMBL5889281 | 0.77 | EPHX2 (0.53) | ALDH1A1HSD17B10EPHX2HTTKMT2A | |
| SCHEMBL5889282 | 0.76 | EPHX2 (0.56) | ALDH1A1EPHX2KMT2AMAPT | |
| SCHEMBL13556180 | 0.75 | ALDH1A1 (0.61) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| Hydrochloric Acid SCHEMBL11532659 | 0.75 | ALDH1A1 (0.52) | ALDH1A1TSHRHSD17B10EPHX2HTT | |
| Hydrochloric Acid SCHEMBL11533621 | 0.73 | ALDH1A1 (0.50) | ALDH1A1TSHRHSD17B10EPHX2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7145037-B2 | Adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them | ROTTA RESEARCH LABORATURIUM S.P.A. (IT) | 2006-12-05 | — | — | US | disclosed |
| EP-1512679-A1 | Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 2005-03-09 | — | — | EP | disclosed |
| US-20050049312-A1 | Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities,and process for preparing them | ROTTA RESEARCH LABORATORIUM S.P.A. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049312-A1 | Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities,and process for preparing them | BDNF, NLN, GAP43 | ALDH1A1 1279/4885TSHR 2622/4885HSD17B10 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.